The American Journal of Managed Care1h
The Silver Lining: Progress and Promise in Combating STIs
With new CDC data expressing optimism about the epidemic of sexually transmitted infections (STIs), take a look at the ...
The American Journal of Managed Care1h
Laryngeal MG is Best Diagnosed with a Tensilon Test or Pyridostigmine Bromide Trial
Recent insights shed light onto the most effective diagnostic tools for laryngeal myasthenia gravis (MG), a poorly understood ...
The American Journal of Managed Care4h
Expanding Access to Gene Therapies: Addressing Patient Burden, High Costs
Gene therapies can be life-changing for people, but the high cost plus the burden of treatment remain barriers to access and ...
The American Journal of Managed Care6h
ICYMI: Highlights From Asembia 2024
Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients ...
The American Journal of Managed Care20h
Cancer Drug Prices Rise in the US Post-Launch, Fall in Germany, Switzerland
The median launch prices in the US increased from $29,630 (IQR, $1322-$49,691) for drugs approved in 201 to $84,240 (IQR, ...
The American Journal of Managed Care23h
New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia
Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small ...
The American Journal of Managed Care19h
Global Burden of Sickle Cell Disease Warrants Universal Access to Hydroxyurea, Experts Say
Experts are now urging the inclusion of sickle cell disease in the global health agenda to address disparities in treatment access. From 2000 to 2021, global births of babies with SCD rose by 13.7%, ...